Euroapi (EAPI) Aktienübersicht
Euroapi S.A. entwickelt, produziert, vermarktet und vertreibt pharmazeutische Wirkstoffe und Zwischenprodukte für die Formulierung von Human- und Tierarzneimitteln. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für EAPI festgestellt.
EAPI Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Euroapi S.A. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | €1.27 |
| 52-Wochen-Hoch | €3.44 |
| 52-Wochen-Tief | €1.22 |
| Beta | 0.97 |
| 1 Monat Veränderung | -12.81% |
| 3 Monate Veränderung | 0.64% |
| 1 Jahr Veränderung | -62.21% |
| 3 Jahre Veränderung | -88.06% |
| 5 Jahre Veränderung | n/a |
| Veränderung seit IPO | -90.63% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 02
EAPI: Weaker Demand And Margin Pressure Will Drag On Future Earnings
Analysts have cut Euroapi's price target sharply, with recent revisions moving from €2.90 to a range of €1.70 and €1. This reflects more cautious assumptions on revenue trends, margins and a higher P/E multiple applied to the stock.
Narrativ-Update • May 10
EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential
Euroapi's analyst price target has shifted lower from about €3.08 to €2.00, with analysts pointing to Deutsche Bank's recent cut in its target to €1, along with updated views on revenue growth, profit margin, discount rate and future P/E assumptions. Analyst Commentary Bullish Takeaways Bullish analysts may see the lower price target range, now clustering around €1 to €2, as setting a more conservative bar for execution, which can reduce the risk of further valuation resets if expectations are now better aligned with current fundamentals.Narrativ-Update • Apr 22
EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings
Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.
Narrativ-Update • Apr 08
EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds
Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.Recent updates
Narrativ-Update • Jun 02
EAPI: Weaker Demand And Margin Pressure Will Drag On Future Earnings
Analysts have cut Euroapi's price target sharply, with recent revisions moving from €2.90 to a range of €1.70 and €1. This reflects more cautious assumptions on revenue trends, margins and a higher P/E multiple applied to the stock.Narrativ-Update • May 10
EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential
Euroapi's analyst price target has shifted lower from about €3.08 to €2.00, with analysts pointing to Deutsche Bank's recent cut in its target to €1, along with updated views on revenue growth, profit margin, discount rate and future P/E assumptions. Analyst Commentary Bullish Takeaways Bullish analysts may see the lower price target range, now clustering around €1 to €2, as setting a more conservative bar for execution, which can reduce the risk of further valuation resets if expectations are now better aligned with current fundamentals.Narrativ-Update • Apr 22
EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings
Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.Narrativ-Update • Apr 08
EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds
Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.Narrativ-Update • Mar 25
EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality
Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.Narrativ-Update • Mar 10
EAPI: Weaker 2025 Guidance Will Pressure Margins And Future Earnings Quality
Analysts have cut their Euroapi price target from €2 to €1, reflecting updated assumptions that now factor in lower revenue growth expectations, much slimmer profit margins, and a significantly higher future P/E multiple. Analyst Commentary Recent price target revisions point to a cautious stance from bearish analysts, who appear focused on execution risks and the implications for Euroapi's valuation.Narrativ-Update • Feb 24
EAPI: Lower 2025 Guidance And Reduced Multiple Will Shape Return Profile
Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing updated assumptions on modest revenue growth, slightly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent research points to a more cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.Narrativ-Update • Feb 09
EAPI: Lower 2025 Outlook And Cautious Stance Will Shape Return Profile
Analysts have lowered their price target on Euroapi from €2.50 to €2, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that collectively suggest a more cautious valuation stance. Analyst Commentary Bearish analysts have recently cut their price target on Euroapi from €2.50 to €2.Narrativ-Update • Jan 25
EAPI: Execution Risks And Lower Outlook Will Shape Future Return Profile
Narrative update Analysts have trimmed their price target on Euroapi by €0.50 to €2.00, citing updated assumptions on revenue growth, profit margins and forward P/E that keep their stance cautious on the shares. Analyst Commentary Recent research has reinforced a cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.00.Narrativ-Update • Jan 10
EAPI: Lower Profitability Assumptions And New Partnership Will Shape Future Returns
Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing softer assumptions around revenue growth, profit margins and a higher future P/E multiple as the key drivers of the reset. Analyst Commentary Bearish analysts are signalling a cautious stance on Euroapi by aligning around a lower price target of €2, narrowed from €2.50.Narrativ-Update • Dec 19
EAPI: Higher Discount Rate Will Outweigh Benefits From New Corticosteroid Partnership
Analysts have slightly reduced their Euroapi price target, reflecting a modest reassessment of fair value. This adjustment accounts for a higher discount rate, even as long term profit margin assumptions edge up and revenue declines appear marginally less severe.Analyseartikel • Dec 18
Calculating The Intrinsic Value Of Euroapi S.A. (EPA:EAPI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €2.68 Euroapi's €2.40 share...Analyseartikel • Dec 18
Euroapi S.A. (EPA:EAPI) Not Doing Enough For Some Investors As Its Shares Slump 26%
Euroapi S.A. ( EPA:EAPI ) shareholders that were waiting for something to happen have been dealt a blow with a 26...Analyseartikel • Oct 03
Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyseartikel • Aug 02
Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates
It's been a mediocre week for Euroapi S.A. ( EPA:EAPI ) shareholders, with the stock dropping 12% to €2.79 in the week...
Neues Narrativ • Mar 31
Capacity Expansion And Efficiency Improvements Will Shape Future Success
Euroapi focuses on high-margin differentiated APIs and CDMO services to boost sustainable revenue and profit margins through strategic project expansions.Analyseartikel • Mar 06
Analyst Estimates: Here's What Brokers Think Of Euroapi S.A. (EPA:EAPI) After Its Annual Report
It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...Analyseartikel • Oct 04
Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 25% Below Its Share Price
Key Insights The projected fair value for Euroapi is €2.62 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Jul 29
There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise
Euroapi S.A. ( EPA:EAPI ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...Analyseartikel • May 24
Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Those holding Euroapi S.A. ( EPA:EAPI ) shares would be relieved that the share price has rebounded 29% in the last...Analyseartikel • Apr 10
Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Mar 03
Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding
The Euroapi S.A. ( EPA:EAPI ) share price has fared very poorly over the last month, falling by a substantial 31%. For...Analyseartikel • Mar 02
Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a major selloff in Euroapi S.A. ( EPA:EAPI ) shares in the week since it released its yearly report, with...Analyseartikel • Dec 21
A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €5.03 With €5.47 share price...Analyseartikel • Aug 04
Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results
It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...Analyseartikel • Aug 02
Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €24.50 Euroapi is estimated to...Analyseartikel • Jun 16
Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity
When close to half the companies operating in the Pharmaceuticals industry in France have price-to-sales ratios (or...Analyseartikel • Jan 25
An Intrinsic Calculation For Euroapi S.A. (EPA:EAPI) Suggests It's 37% Undervalued
Key Insights Euroapi's estimated fair value is €21.9 based on 2 Stage Free Cash Flow to Equity Current share price of...Aktionärsrenditen
| EAPI | FR Pharmaceuticals | FR Markt | |
|---|---|---|---|
| 7D | 0% | -1.5% | 1.8% |
| 1Y | -62.2% | -6.5% | 5.2% |
Rendite im Vergleich zur Industrie: EAPI unter dem Niveau der Branche French Pharmaceuticals , die im vergangenen Jahr eine Rendite von -6.5% erzielte.
Rendite vs. Markt: EAPI hinter dem Markt French zurück, der im vergangenen Jahr eine Rendite von 5.2 erzielte.
Preisvolatilität
| EAPI volatility | |
|---|---|
| EAPI Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FR Market | 10.9% |
| 10% least volatile stocks in FR Market | 2.8% |
Stabiler Aktienkurs: EAPI hatte in den letzten 3 Monaten im Vergleich zum French -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: EAPIDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2020 | 2,961 | David Seignolle | www.euroapi.com/en |
Euroapi S.A. entwickelt, produziert, vermarktet und vertreibt pharmazeutische Wirkstoffe und Zwischenprodukte, die bei der Formulierung von Human- und Tierarzneimitteln zum Einsatz kommen. Das Unternehmen bietet eine Organisation zur Auftragsentwicklung und -herstellung für verschiedene Klassen von Gezeiten, die Festphasenchemie, Partikeltechnik, mikrobielle Fermentation, Synthese kleiner Moleküle, Prostaglandine, Steroide und Hormone, Opiate und kontrollierte Substanzen sowie Lipide verwendet. Das Unternehmen bietet seine Produkte Herstellern von Pharmazeutika, Generika, Tierarzneimitteln, Konsumgütern, Nahrungsmitteln und kosmetischen Produkten, Biotechnologieunternehmen und Vertriebsunternehmen sowie Auftragsentwicklungs- und -herstellungsunternehmen an.
Euroapi S.A.'s Grundlagenzusammenfassung
| EAPI grundlegende Statistiken | |
|---|---|
| Marktanteil | €120.51m |
| Gewinn(TTM) | -€211.20m |
| Umsatz(TTM) | €852.60m |
0.1x
Kurs-Umsatz-Verhältnis-0.6x
Kurs-Gewinn-Verhältnis Ist EAPI zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| EAPI Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | €852.60m |
| Kosten der Einnahmen | €707.70m |
| Bruttogewinn | €144.90m |
| Sonstige Ausgaben | €356.10m |
| Gewinn | -€211.20m |
Zuletzt gemeldete Gewinne
Dec 31, 2025
Datum des nächsten Gewinnberichts
Jul 28, 2026
| Gewinn per Aktie (EPS) | -2.22 |
| Bruttomarge | 17.00% |
| Nettogewinnspanne | -24.77% |
| Schulden/Eigenkapital-Verhältnis | 5.8% |
Wie hat sich EAPI auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/14 17:03 |
| Aktienkurs zum Tagesende | 2026/06/12 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Euroapi S.A. wird von 11 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Justin Steven Smith | Bernstein |
| Patrick Andrew Wood | BofA Global Research |
| Fynn Scherzler | Deutsche Bank |